Lead Product(s) : GBP560
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SK bioscience Starts Global Trials for JE Vaccine
Details : GBP560 is an mRNA-based vaccine candidate, which is being evaluated for the treatment of japanese encephalitis virus disease in adults.
Product Name : GBP560
Product Type : Vaccine
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : GBP560
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBP560
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SK Bioscience Approved for Global Trials of mRNA Japanese Encephalitis Vaccine
Details : GBP560 is a mRNA-based Japanese encephalitis vaccine candidate which is currently being evaluated for the treatment of japanese encephalitis virus disease.
Product Name : GBP560
Product Type : Vaccine
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : GBP560
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBP510
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK and SK bioscience's COVID Vaccine Submitted for S.Korea Approval
Details : Protein-based SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 ‘GBP510’ with GSK pandemic adjuvant demonstrates superior neutralising titres compared to a control vaccine and clinically favourable safety profile.
Product Name : GBP510
Product Type : Vaccine
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : GBP510
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EuCorVac-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Korea Institute of Science and Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested.
Product Name : EuCorVac-19
Product Type : Vaccine
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : EuCorVac-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Korea Institute of Science and Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBP510
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $26.7 million
Deal Type : Funding
CEPI and SK Bioscience Expand Partnership to Develop Vaccine Against Covid-19 Variants
Details : CEPI will provide up to $14.2 million to support the adaptation of SK bioscience’s recombinant protein vaccine candidate (GBP510) for use against “variants of concern”, such as the B.1.351 variant first identified in South Africa.
Product Name : GBP510
Product Type : Vaccine
Upfront Cash : Undisclosed
October 03, 2021
Lead Product(s) : GBP510
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $26.7 million
Deal Type : Funding
Lead Product(s) : GBP510
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $210.1 million
Deal Type : Funding
Details : Funding will support Phase 3 trials of SK bioscience’s recombinant protein vaccine candidate (GBP510) and adaptation for use against multiple variants of concern.
Product Name : GBP510
Product Type : Vaccine
Upfront Cash : Undisclosed
May 24, 2021
Lead Product(s) : GBP510
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $210.1 million
Deal Type : Funding
Lead Product(s) : GX-19N
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Genexine
Deal Size : Undisclosed
Deal Type : Agreement
S.Korea's Genexine Signs COVID-19 Vaccine Candidate Manufacturing Deal with Hanmi
Details : Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of...
Product Name : GX-19N
Product Type : Vaccine
Upfront Cash : Undisclosed
May 18, 2021
Lead Product(s) : GX-19N
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Genexine
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : GX-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genexine Expected to Apply for Approval of Covid-19 Vaccine Next Fall
Details : Genexine expects to obtain full data from a Phase I trial of its DNA vaccine GX-19 late this year or early next year, while starting a Phase IIa study within this year and concurrent Phase IIb and III trials in the first half of next year.
Product Name : GX-19
Product Type : Vaccine
Upfront Cash : Inapplicable
November 15, 2020
Lead Product(s) : GX-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GX-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genexine, COVID-19 Preventive Vaccine, GX-19, clinical 1/2 Phase Approval
Details : First domestic pharmaceutical company to have been approved for clinical phase 1/2a of GX-19, which is a DNA vaccine against COVID-19, by the Ministry of Food and Drug Safety.
Product Name : GX-19
Product Type : Vaccine
Upfront Cash : Inapplicable
November 06, 2020
Lead Product(s) : GX-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBP510
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $10.0 million
Deal Type : Collaboration
CEPI and SK Bioscience Extend Collaboration to Develop ‘Next Generation’ Covid-19 Vaccine
Details : CEPI will contribute up to $10 million towards the cost of a phase I/II study of a recombinant protein vaccine candidate (GBP510)—manufactured using a nanoparticle platform—and manufacture of clinical trial materials needed for phase I/II and phase I...
Product Name : GBP510
Product Type : Vaccine
Upfront Cash : Undisclosed
September 12, 2020
Lead Product(s) : GBP510
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $10.0 million
Deal Type : Collaboration